We are live on ! Find out more
LCG

Lisanti Capital Growth Portfolio holdings

AUM $397M
1-Year Est. Return 178.66%
This Fund
S&P 500
This Quarter Est. Return
+25.71%
1 Year Est. Return
+178.66%
3 Year Est. Return
+1,089.72%
5 Year Est. Return
+3,176.57%
10 Year Est. Return
+120,936.2%
AUM
$200M
AUM Growth
+$1.02M
Cap. Flow
-$29.1M
Cap. Flow %
-14.57%
Top 10 Hldgs %
21.02%
Holding
130
New
37
Increased
23
Reduced
29
Closed
41

Sector Composition

Rank Sector Weight
1 Healthcare 25.63%
2 Technology 19.58%
3 Consumer Discretionary 18.44%
4 Industrials 9.82%
5 Financials 5.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NPSP
126
DELISTED
NPS PHARMACEUTICALS INC
NPSP
-24,000
Closed -$624K
BDSI
127
DELISTED
BioDelivery Sciences International, Inc.
BDSI
-72,055
Closed -$1.23M
WLH
128
DELISTED
WILLIAM LYON HOMES
WLH
-74,715
Closed -$1.65M
EFII
129
DELISTED
Electronics for Imaging
EFII
-43,440
Closed -$1.92M
LPNT
130
DELISTED
LifePoint Health, Inc.
LPNT
-45,865
Closed -$3.17M

Similar funds

Lisanti Capital Growth's Q4 2014 Portfolio in Review

As of Q4 2014, Lisanti Capital Growth held 130 positions worth $200M, up 0.51% from $199M the previous quarter. Its ten largest holdings account for 21% of the portfolio.

Lisanti Capital Growth withdrew a net $29.1M in Q4 2014, closing 41 positions and reducing 29 holdings. Its most notable exit was Pacira BioSciences, an estimated $4.68M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, up from 25% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Lisanti Capital Growth opened a new position in Axon Enterprise worth $4.42M.

  • Lisanti Capital Growth's largest Q4 2014 buy was Axon Enterprise: 166,777 shares worth $4.42M.
  • Lisanti Capital Growth added most to Paylocity in Q4 2014, an estimated $1.16M increase.
  • Lisanti Capital Growth's biggest Q4 2014 reduction was Team Health Holdings Inc, cutting an estimated $2.02M.
  • Lisanti Capital Growth fully exited Pacira BioSciences in Q4 2014, selling an estimated $4.68M.
  • Lisanti Capital Growth's ten largest holdings make up 21% of its $200M portfolio in Q4 2014.
  • Lisanti Capital Growth opened 37 new positions and closed 41 in Q4 2014.
  • Lisanti Capital Growth's portfolio value rose 0.51% quarter-over-quarter to $200M.

Based on Lisanti Capital Growth's 13F filing for Q4 2014, filed 10 Feb 2015.